Now You See It, Now You Don't!—Spontaneous Complete Necrosis and Reappearance of Hepatocellular Carcinoma

Abstract

Spontaneous regression of hepatocellular carcinoma (HCC) is a rare phenomenon caused by complex multifactorial mechanisms. We report the case of a 76-year-old male with a history of chronic liver disease and HCC who experienced complete spontaneous tumor regression followed by recurrence. The regression may have been triggered by ischemia from portal vein thrombosis and systemic inflammation. Key mechanisms behind spontaneous regression include tumor hypoxia and immune responses. This case highlights the complexity of spontaneous regression and its potential role in developing novel cancer therapies.

Keywords

ischemia - hypoxia - cirrhosis - thrombus - cytokine - immune

Publication History

Article published online:
02 April 2025

• References

• 1 Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol 1981; 17 (03) 201-209
• 2 Salman T. Spontaneous tumor regression. Journal of Oncological Science. 2016; 2
• 3 Cole WH. Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr 1976; 44: 5-9
• 4 Cheng HM, Tsai MC. Regression of hepatocellular carcinoma spontaneous or herbal medicine related?. Am J Chin Med 2004; 32 (04) 579-585
• 5 Chien RN, Chen TJ, Liaw YF. Spontaneous regression of hepatocellular carcinoma. Am J Gastroenterol 1992; 87 (07) 903-905
• 6 Kato H, Nakamura M, Muramatsu M, Orito E, Ueda R, Mizokami M. Spontaneous regression of hepatocellular carcinoma: two case reports and a literature review. Hepatol Res 2004; 29 (03) 180-190
• 7 Takeda Y, Togashi H, Shinzawa H. et al. Spontaneous regression of hepatocellular carcinoma and review of literature. J Gastroenterol Hepatol 2000; 15 (09) 1079-1086
• 8 Storey RE, Huerta AL, Khan A, Laber DA. Spontaneous complete regression of hepatocellular carcinoma. Med Oncol 2011; 28 (04) 948-950
• 9 Gottfried EB, Steller R, Paronetto F, Lieber CS. Spontaneous regression of hepatocellular carcinoma. Gastroenterology 1982; 82 (04) 770-774
• 10 McCaughan GW, Bilous MJ, Gallagher ND. Long-term survival with tumor regression in androgen-induced liver tumors. Cancer 1985; 56 (11) 2622-2626
• 11 Gaffey MJ, Joyce JP, Carlson GS, Esteban JM. Spontaneous regression of hepatocellular carcinoma. Cancer 1990; 65 (12) 2779-2783
• 12 Ohba K, Omagari K, Nakamura T. et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998; 43 (04) 575-577
• 13 Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB (Oxford) 2012; 14 (08) 500-505
• 14 O'Beirne JP, Harrison PM. The role of the immune system in the control of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004; 16 (12) 1257-1260
• 15 Goto Y, Uchino Y, Sasaki S. et al. Complete spontaneous necrosis of hepatocellular carcinoma accompanied by portal vein tumor thrombosis: a case report. Int J Surg Case Rep 2018; 44: 220-225
• 16 Kimura T, Goi T, Yokoi S. et al. Possible spontaneous regression of hepatocellular carcinoma with unique histopathological features confirmed by surgical resection: a case report. Surg Case Rep 2021; 7 (01) 162
• 17 Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res 2010; 40 (10) 943-953
• 18 Abiru S, Kato Y, Hamasaki K, Nakao K, Nakata K, Eguchi K. Spontaneous regression of hepatocellular carcinoma associated with elevated levels of interleukin 18. Am J Gastroenterol 2002; 97 (03) 774-775
• 19 Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression–a single case report. Curr Med Res Opin 2003; 19 (01) 59-63
• 20 Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27 (02) 407-414
• 21 Serrano PE, Parpia S, Linkins LA. et al. Venous thromboembolic events following major pelvic and abdominal surgeries for cancer: a prospective cohort study. Ann Surg Oncol 2018; 25 (11) 3214-3221
• 22 Connolly GC, Chen R, Hyrien O. et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008; 122 (03) 299-306
• 23 Velázquez RF, Rodríguez M, Navascués CA. et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37 (03) 520-527
• 24 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
• 25 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
• 26 Zanetto A, Campello E, Spiezia L, Burra P, Simioni P, Russo FP. Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma. Cancers (Basel) 2018; 10 (11) 450
• 27 Zanetto A, Senzolo M, Vitale A. et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49 (04) 440-445
• 28 Hwang SJ, Luo JC, Li CP. et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10 (17) 2472-2477
• 29 Carr BI, Guerra V, Giannini EG. et al; Italian Liver Cancer Group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers 2014; 29 (03) e215-e223